Last updated: 07/17/2024 15:18:10
Evaluation of long-term immunogenicity and safety of a Human Papillomavirus (HPV) vaccine in healthy female subjects.
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Follow-up study to evaluate the long-term immunogenicity and safety of a HPV vaccine (GSK 580299) in healthy female subjects
Trial description: Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. This study is designed to evaluate the long-term immunogenicity and safety of the 580299 HPV vaccine up to 10 years after administration of the first dose of HPV vaccine (Month 0) administered in the primary study 580299/013. This protocol posting deals with objectives & outcome measures of the extension phase from Month 60 to Month 120. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT00196924). The objectives & outcome measures of the extension phase up to Month 48 are presented in a separate protocol posting (NCT00316706).
Primary purpose:
Prevention
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:
Number of seroconverted subjects with anti-HPV-16/18 antibody titers equal to or above cut-off values.
Timeframe: At Month 60
Number of seroconverted subjects with anti-HPV-16/18 antibody titers equal to or above cut-off values.
Timeframe: At Month 72
Number of seroconverted subjects with anti-HPV-16/18 antibody titers equal to or above cut-off values.
Timeframe: At Month 84
Number of seroconverted subjects with anti-HPV-16/18 antibody titers equal to or above cut-off values.
Timeframe: At Month 96
Anti-human papillomavirus-16 and 18 (anti-HPV-16/18) antibody titers
Timeframe: At Month 60
Anti-human papillomavirus-16 and 18 (anti-HPV-16/18) antibody titers
Timeframe: At month 72
Anti-human papillomavirus-16 and 18 (anti-HPV-16/18) antibody titers
Timeframe: At Month 84
Anti-human papillomavirus-16 and 18 (anti-HPV-16/18) antibody titers
Timeframe: At Month 96
Number of seroconverted subjects with anti-HPV-16/18 antibody titers equal to or above cut-off values.
Timeframe: At Month 108
Anti-human papillomavirus-16 and 18 (anti-HPV-16/18) antibody titers
Timeframe: At Month 108
Anti-human papillomavirus-16 and 18 (anti-HPV-16/18) antibody titers
Timeframe: At Month 120
Number of seroconverted subjects with anti-HPV-16/18 antibody titers equal to or above cut-off values.
Timeframe: At Month 120
Secondary outcomes:
Number of subjects with serious adverse events (SAEs)
Timeframe: From Month 48 to Month 60
Number of subjects with serious adverse events (SAEs)
Timeframe: From Month 60 to Month 72
Number of subjects with serious adverse events (SAEs)
Timeframe: From Month 72 to Month 84
Number of subjects with serious adverse events (SAEs)
Timeframe: From Month 84 to Month 96
Number of subjects with serious adverse events (SAEs)
Timeframe: From Month 96 to Month 108
Number of subjects with serious adverse events (SAEs)
Timeframe: From Month 108 to Month 120
Interventions:
Enrollment:
632
Primary completion date:
2015-06-01
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Schwarz TF et al. (2014) Long-term Immunogenicity and Safety of the HPV-16/18 AS04-adjuvanted Vaccine in 10- to 14-year-old Girls: Open 6-year Follow-up of an Initial Observer-blinded, Randomized Trial. Pediatr Infect Dis J. 33(12):1255-1261.
Schwarz TF et al. (2019) A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Hum Vaccin Immunother. 15(7-8):1970-1979. doi: 10.1080/21645515.2019.1625644.
Medical condition
Infections, Papillomavirus
Product
SB580299
Collaborators
Not applicable
Study date(s)
May 2009 to January 2015
Type
Interventional
Phase
3
Participation criteria
Sex
Female
Age
15 - 24 years
Accepts healthy volunteers
Yes
- Subjects who the investigator believes that they and/or their parents or legally acceptable representative (LAR) can and will comply with the requirements of the protocol should be enrolled in the study.
- A female enrolled in the immunogenicity subset of study 580299-013, who received three doses of HPV vaccine and participated in the extension study of 580299-013.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects who the investigator believes that they and/or their parents or legally acceptable representative (LAR) can and will comply with the requirements of the protocol should be enrolled in the study.
- A female enrolled in the immunogenicity subset of study 580299-013, who received three doses of HPV vaccine and participated in the extension study of 580299-013.
- Written informed assent obtained from the subject. For subjects below the legal age of consent, written informed consent must be obtained from a parent or legally acceptable representative of the subject.
Exclusion criteria:
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.
- Administration or planned administration of any HPV vaccine, other than the vaccine administered in study 580299-013.
- Chronic administration of immunosuppressants or other immune-modifying drugs occurring within the three months preceding study entry.
- Administration of immunoglobulins and/or any blood products occurring within the three months preceding study entry.
Trial location(s)
Location
GSK Investigational Site
Bochum, Nordrhein-Westfalen, Germany, 44866
Status
Study Complete
Location
GSK Investigational Site
Buetzow, Mecklenburg-Vorpommern, Germany, 18246
Status
Study Complete
Showing 1 - 6 of 26 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2015-06-01
Actual study completion date
2015-06-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website